Table 3.
Management-related variables and unadjusted odds ratios for vancomycin-associated acute kidney injury
|
n = 415 n (%) or median (IQR) |
Odds ratio (95% confidence interval) | P value | |
|---|---|---|---|
| Radiological test performed | 240 (57.8) | 1.514 (0.755–3.038) | 0.240 |
| X-ray | 100 (24.1) | ||
| CT-scan | 101 (24.3) | ||
| Ultrasound | 66 (15.9) | ||
| MRI | 34 (8.2) | ||
| Surgical consult | 255 (61.4) | 1.461 (0.718–2.973) | 0.294 |
| Dermatology consult | 8 (1.9) | 0.979 (0.964–0.993) | 1.000 |
| Infectious diseases consult | 240 (57.8) | 1.514 (0.755–3.038) | 0.240 |
| Source control procedure | 174 (41.9) | 0.960 (0.491–1.876) | 0.905 |
| Bedside incision and drainage | 62 (14.9) | ||
| OR incision and drainage | 100 (24.1) | ||
| Debridement | 10 (2.4) | ||
| Amputation | 5 (1.2) | ||
| Concomitant antipseudomonal antibiotic ≥ 72 h | 178 (42.9) | 2.603 (1.311–5.168) | 0.006 |
| Cefepime | 84 (20.2) | 1.407 (0.657–3.016) | 0.380 |
| Piperacillin-tazobactam | 83 (20.0) | 2.831 (1.411–5.681) | 0.003 |
| Receipt of IV contrast dye | 97 (23.4) | 2.241 (1.124–4.468) | 0.019 |
| Concomitant nephrotoxic drug ≥ 48 h | 257 (61.9) | 2.572 (1.151–5.748) | 0.021 |
| Piperacillin-tazobactam | 86 (20.7) | 2.685 (1.340–5.379) | 0.005 |
| Vasopressors | 2 (0.5) | 9.868 (0.605–160.960) | 0.179 |
| Loop diuretic | 81 (19.5) | 1.977 (0.954–4.097) | 0.063 |
| ACE-inhibitor | 64 (15.4) | 1.224 (0.515–2.908) | 0.646 |
| Angiotensin receptor blocker | 25 (6.0) | 0.830 (0.188–3.659) | 1.000 |
| Tenofovir disoproxil fumarate | 4 (1.0) | 3.272 (0.332–32.234) | 0.327 |
| Non-steroidal anti-inflammatory | 79 (19.0) | 0.600 (0.227–1.587) | 0.299 |
| Acyclovir | 5 (1.2) | 6.721 (1.088–41.513) | 0.018 |
ACE angiotensin converting enzyme, IV intravenous; operating room
an = 257